Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip T James

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|February 24, 2015
Child and adolescent obesity: part of a bigger pictureTim Lobstein, Rachel Jackson-Leach, Marjory L Moodie, et al.
The Journal of Nutrition|June 10, 2022
How Can Nutrition Research Better Reflect the Relationship Between Wasting and Stunting in Children? Learnings from the Wasting and Stunting ProjectKate Sadler, Philip T James, Zulfiqar A Bhutta, et al.
Diabetes Care|October 4, 2013
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trialAdam Ali Ghotbi, Lars Køber, Nick Finer, et al.
Obesity Research|February 26, 2004
The high prevalence of overweight and obesity in Mexican childrenBlanca E del Río-Navarro, Oscar Velázquez-Monroy, Claudia P Sánchez-Castillo, et al.
Plos One|March 28, 2013
Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individualsHelle Skak-Nielsen, Christian Torp-Pedersen, Nick Finer, et al.
Nutrition & Metabolism|October 16, 2009
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trialCharlotte Andersson, Peter Weeke, Bente Brendorp, et al.
BMC Endocrine Disorders|February 27, 2010
The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in periodPeter Weeke, Charlotte Andersson, Emil L Fosbøl, et al.
Circulation|October 7, 2009
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of ObesityK G M M Alberti, Robert H Eckel, Scott M Grundy, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 22, 2016
Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trialAldo P Maggioni, Ian D Caterson, Renato Urso, et al.
The New England Journal of Medicine|September 8, 2010
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjectsW Philip T James, Ian D Caterson, Walmir Coutinho, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|February 24, 2015
Child and adolescent obesity: part of a bigger pictureTim Lobstein, Rachel Jackson-Leach, Marjory L Moodie, et al.
The Journal of Nutrition|June 10, 2022
How Can Nutrition Research Better Reflect the Relationship Between Wasting and Stunting in Children? Learnings from the Wasting and Stunting ProjectKate Sadler, Philip T James, Zulfiqar A Bhutta, et al.
Diabetes Care|October 4, 2013
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trialAdam Ali Ghotbi, Lars Køber, Nick Finer, et al.
Obesity Research|February 26, 2004
The high prevalence of overweight and obesity in Mexican childrenBlanca E del Río-Navarro, Oscar Velázquez-Monroy, Claudia P Sánchez-Castillo, et al.
Plos One|March 28, 2013
Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individualsHelle Skak-Nielsen, Christian Torp-Pedersen, Nick Finer, et al.
Nutrition & Metabolism|October 16, 2009
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trialCharlotte Andersson, Peter Weeke, Bente Brendorp, et al.
BMC Endocrine Disorders|February 27, 2010
The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in periodPeter Weeke, Charlotte Andersson, Emil L Fosbøl, et al.
Circulation|October 7, 2009
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of ObesityK G M M Alberti, Robert H Eckel, Scott M Grundy, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 22, 2016
Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trialAldo P Maggioni, Ian D Caterson, Renato Urso, et al.
The New England Journal of Medicine|September 8, 2010
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjectsW Philip T James, Ian D Caterson, Walmir Coutinho, et al.
Pageof 5